Because little comparative information is available concerning receptor profiles of antiparkinson drugs, affinities of 14 agents were determined at diverse receptors implicated in the etiology and/or treatment of Parkinson's disease: human (h)D 1 , hD 2S , hD 2L , hD 3 , hD 4 , and hD 5 receptors; human 5-hydroxytryptamine (5-HT) 1A , h5-HT 1B , h5-HT 1D , h5-HT 2A , h5-HT 2B , and h5-HT 2C receptors; h␣ 1A -, h␣ 1B -, h␣ 1D -, h␣ 2A -, h␣ 2B -, h␣ 2C -, rat ␣ 2D -, h␤ 1 -, and h␤ 2 -adrenoceptors (ARs); and native histamine 1 receptors. A correlation matrix (294 pK i values) demonstrated substantial "covariance". Correspondingly, principal components analysis revealed that axis 1, which accounted for 76% variance, was associated with the majority of receptor types: drugs displaying overall high versus modest affinities migrated at opposite extremities. Axis 2 (7% of variance) differentiated drugs with high affinity for hD 4 and H 1 receptors versus h␣ 1 -AR subtypes. Five percent of variance was attributable to axis 3, which distinguished drugs with marked affinity for h␤ 1 -and h␤ 2 -ARs versus hD 5 and 5-HT 2A receptors. Hierarchical (cluster) analysis of global homology generated a dendrogram differentiating two major groups possessing low versus high affinity, respectively, for multiple serotonergic and hD 5 receptors. Within the first group, quinpirole, quinerolane, ropinirole, and pramipexole interacted principally with hD 2 , hD 3 , and hD 4 receptors, whereas piribedil and talipexole recognized dopaminergic receptors and h␣ 2 -ARs. Within the second group, lisuride and terguride manifested high affinities for all sites, with roxindole/bromocriptine, cabergoline/pergolide, and 6,7-dihydroxy-N,N-dimethyl-2-ammotetralin (TL99)/apomorphine comprising three additional subclusters of closely related ligands. In conclusion, an innovative multivariate analysis revealed marked heterogeneity in binding profiles of antiparkinson agents. Actions at sites other than hD 2 receptors likely participate in their (contrasting) functional profiles.
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In Parkinson's disease, the progressive degeneration of nigrostriatal dopaminergic pathways is associated with diverse motor symptoms, including rigidity, tremor, bradykinesia, and postural instability (Jenner, 1995) . In addition, patients present, often precociously, sensory and cognitiveattentional deficits together with depressed mood (Jenner, 1995) . Despite increasing interest in neuroprotective strategies, Parkinson's Disease is principally treated by administration of the dopamine (DA) precursor L-dihydroxyphenylalanine (L-DOPA) (Bezard et al., 2001) . However, there is evidence, albeit contentious, that L-DOPA exacerbates damage to dopaminergic neurons (Zou et al., 1999) . Furthermore, L-DOPA displays variable pharmacokinetics, elicits dyskinesias and autonomic side effects, poorly improves certain motor symptoms, is largely ineffective against cognitive and mood deficits, and loses efficacy upon prolonged administration (Bezard et al., 2001) . Abrupt transitions between "on" and "off" phases are particularly distressing to patients (Jenner, 1995) . In light of these observations, the management of Parkinson's Disease by drugs directly stimulating postsynaptic DA receptors is of interest (Jenner, 1995; Montastruc et al., 1999) . Such dopaminergic agents possess neuroprotective properties, mediated by both dopaminergic (autoreceptor) and nondopaminergic mechanisms (Zou et al., 1999) and elicit less marked dyskinesia (Uitti and Ahlskog, 1996; Rascol et al., 2000) . Furthermore, they may improve mood and cognitive function (Weddell and Weiser, 1995; Nagaraja and Jayashree, 2001 ). In addition to adjunctive therapy, recent studies support the long-term efficacy of dopaminergic agonists in monotherapy, thereby delaying the introduction of L-DOPA (Rascol et al., 2000) . Nevertheless, "sleep-attacks", sedation, and both psychiatric and cardiovascular side effects complicate utilization of dopaminergic agonists (Friedman and Factor, 2000) .
The above-mentioned panoply of desirable and undesirable actions varies among antiparkinson agents (Uitti and Ahlskog, 1996) . Such differences likely reflect contrasting patterns of interactions at sites other than dopamine D 2 receptors (Uitti and Ahlskog, 1996) . D 3 receptors are of particular interest, although it remains controversial as to whether their engagement contributes to therapeutic and/or psychiatric and motor side effects (Millan et al., 2000b; Joyce, 2001) . Activation of D 4 receptors does not, on the other hand, participate in the improvement of Parkinson's Disease (Newman-Tancredi et al., 1997; Oak et al., 2000) . Although D 1 receptor agonists display antiparkinson activity in experimental models, their clinical efficacy upon long-term administration remains uncertain, and their stimulation is not obligatory for therapeutic activity (Jenner, 1995; Gulwadi et al., 2001) . Furthermore, the relative roles of D 1 versus closely related D 5 sites remain unclear (see Discussion).
Inasmuch as 1) Parkinson's Disease is aggravated by degeneration of locus coeruleus-derived adrenergic and raphederived serotonergic pathways (Brefel-Courbon et al., 1998; Jellinger, 1999) ; and 2) adrenergic and serotonergic mechanisms modulate dopaminergic transmission, motor behavior, mood, and cognitive function (Meneses, 1999; Millan et al., 2000c) , it is important to consider potential actions of antiparkinson agents at adrenoceptors (ARs) and 5-HT receptors. Although surprisingly little information is available, talipexole and 6,7-dihydroxy-N,N-dimethyl-2-ammotetralin (TL99) are known to possess agonist properties at native ␣ 2 -ARs (Horn et al., 1982; Meltzer et al., 1989) . In contrast, blockade of ␣ 2 -ARs by piribedil reinforces frontocortical adrenergic, dopaminergic, and cholinergic transmission and favorably influences mood and cognitive-attentional function (Millan et al., 2000c (Millan et al., , 2001a Maurin et al., 2001; Nagaraja and Jayashree, 2001; Gobert et al., 2002) . In addition to antagonist actions at ␣ 2 -and ␣ 1 -ARs, bromocriptine reveals pronounced affinity for 5-HT 1A receptors (McPherson and Beart, 1983; Jackisch et al., 1985; Uitti and Ahlskog, 1996) . Other antiparkinson agents known to recognize 5-HT 1A and/or 5-HT 2A receptors are lisuride, terguride, and roxindole (Jackson et al., 1995; Uitti and Ahlskog, 1996) .
The purpose of the present studies was to consolidate these fragmentary data by evaluating the actions of 14 dopaminergic agonists (antiparkinson agents) at multiple classes of monoaminergic receptor. In addition, actions at muscarinic (M 1 ) sites and histamine (H) 1 sites were evaluated in light of 1) their role in the control of motor behavior, mood, and cognition (Bacciottini et al., 2001; Brown et al., 2001) ; 2) alterations in histaminergic and cholinergic transmission in Parkinson's Disease (Jellinger, 1999; Anichtchik et al., 2000) ; and 3) the use of anticholinergic agents for management of refractory tremor (Wilms et al., 1999) . The strategy adopted was as follows. First, using competition binding assays, drug affinities were determined at recombinant, stably transfected, human receptors as well as at rat ␣ 2D -ARs 1 and at native H 1 receptors. Second, to facilitate analysis of the extensive database and comparisons of drug profiles, a correlation matrix was constructed: data were subjected to principle components analysis (PCA) and then drugs were classified by hierarchical (cluster) analysis in accordance with their overall homology. This innovative multivariate approach to drug comparisons has the advantage that it is not founded upon specific hypotheses requiring testing via post hoc, inferential statistics. Rather, by fully and simultaneously exploring total variance, it permits the objective identification and interpretation of hidden patterns not revealed by visual inspection or drug-by-drug/receptor-by-receptor comparisons (Krzanowski, 2000; Millan et al., 2000a; Carlsson et al., 2001 ). Third, as described in the accompanying articles (Newman-Tancredi et al., 2002a,b) , efficacies of antiparkinson agents were determined at (the majority of) monoaminergic receptor subtypes incorporated into these multivariate analyses.
Materials and Methods
Determination of Drug Affinities. Procedures used for the determination of drug affinities have been described in detail previously (Newman-Tancredi et al., 1997; Millan et al., 2001a) . They are summarized in Tables 1, 2 , and 3. Isotherms were subjected to nonlinear regression analysis by use of the program PRISM (GraphPad Software, San Diego, CA) to yield IC 50 values. These were subsequently transformed into K i values according to the Cheng- Prussof equation
where L corresponds to the radioligand concentration and K d to its dissociation constant. Multivariate Analysis: Principal Components Analysis. The database used for multivariate analysis comprised the affinities ("parameters") for 14 drugs at (21) separate receptors ("variables") indicated in Tables 4, 5, and 6. (pK i values of Ͻ5.0 were considered as 5.0 for these analyses.) Because all parameters are intrinsically equivalent, they were not transformed ("standardized"): pK i values are the negative logarithmic expression of affinities. After construction of a correlation matrix (Pearson product-moment coefficients) across all parameters (Table 7) , the database was subjected to PCA (Krzanowski, 2000) using SPAD-3, a computer program developed by the Centre International de Statistiques et d'Informatiques Appliquées (St. Mandé, France). This generates a "multidimensional space" of 21 axes from the database, with all axes mathematically "perpendicular" to each other. The first axis, principal component (PC)1, represents the linear combination of all parameters (affinities) in the data set that accounts for the maximal possible variance. Correspondingly, loading values (correlation coefficients) in Table 8 indicate the contribution of individual parameters to PC1. Successive axes (PC2 onwards) account for progressively less variance. PCs 1 to 3, which accounted for a substantial majority of variance (see Results), were two-dimensionally represented in scatter diagrams ("biplots") upon which drugs were superimposed together with the parameters underlying their dispersion.
Multivariate Analysis: Hierarchical Cluster Analysis. After PCA, and likewise exploiting SPAD-3, drugs were hierarchically ("cluster") classified in accordance with their overall homology to yield a binary dendrogram (Krzanowski, 2000) . Using an "agglomeration" algorithm, the array of drugs was progressively ("hierarchically") fused into subclusters and clusters until it comprised a single group. With the formation of each successive cluster, the loss of "objective function value" (information) was constrained as much as possible, that is, the intragroup compared with intergroup variance was minimized. The length of bars between pairs of drugs in the two-dimensional dendrogram reflects their dissimilarity, that is, the shorter the distance, the more closely related the pairs of drugs. 
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Nodes on the dendrogram therefore represent the consecutive aggregation of two individual elements (drugs or drug clusters). Radar Plots. "Radar" representations of binding profiles at certain key receptors were constructed to further visualize similarities and differences in drug binding profiles.
Drugs. Pramipexole dihydrochloride, piribedil hydrochloride, and ropinirole were synthesized by Institut de Recherches Servier (Paris, France). Lisuride maleate and terguride were donated by Schering (Berlin, Germany); bromocriptine, (Ϫ)-quinpirole, pergolide, and TL99 were purchased from Sigma/RBI (Natick, MA); apomorphine hydrochloride was purchased from Sigma (St. Quentin Fallavier, France); and roxindole was donated by Merck (Darmstadt, Germany) and talipexole (BHT-920) by Boehringer Ingelheim GmbH (Ingelheim, Germany). Cabergoline was obtained from Farmitalia Carlo Erba (Rueil-Malmaison, France). Quinelorane dihydrochloride was a gift from Eli Lilly & Co. (Indianapolis, IN).
Results
General Comments. In view of the large number of drugs and binding sites examined, a detailed text description of all (ϳ300) interactions cannot be presented below. Full data are shown in Tables 4 to 7 .
Dopamine hD 2S , hD 2L , hD 3 , and hD 4 Receptors. There was a substantial (5000-fold) range in drug affinities at hD 2S receptors (Table 4) .
2 For example, the affinity of cabergoline was very pronounced compared with that of pramipexole. At hD 2L receptors (which possess a 29 amino acid insert in the third intracellular loop), affinities of drugs likewise varied broadly and were similar to those at hD 2S sites. There was likewise marked (ϳ1000-fold) variability in drug affinities at hD 3 sites. The ratio of drug affinities at hD 3 compared with hD 2L and hD 2S sites differed considerably from modest (e.g., cabergoline and pergolide) to pronounced (e.g., pramipexole). The variation in drug affinities at hD 4 receptors was also striking (ϳ400-fold). Certain drugs displayed considerably higher affinities at hD 4 versus hD 2S /hD 2L sites (such as apomorphine), whereas others showed modest differences (such as piribedil) or a marked preference for hD 2S /hD 2L sites (such as bromocriptine).
Dopamine hD 1 and hD 5 Receptors. Drug affinities for hD 1 sites were substantially lower than for hD 2S and hD 2L receptors: apomorphine and cabergoline showed the least and most pronounced difference, respectively (Table 4) . There was ϳ200-fold variability in drug affinities at hD 1 sites with certain agents, including pramipexole, displaying negligible affinity. For all drugs manifesting significant affinity for hD 1 receptors, affinities were higher at hD 5 receptors. This difference was mild for certain drugs, such as bromocriptine, and pronounced for others, such as pergolide.
h␣ 1A -, h␣ 1B -, and h␣ 1D -ARs. For each drug, affinities at h␣ 1A -, h␣ 1B -, and h␣ 1D -ARs were similar (Table 5) . Affinities varied over a ϳ10,000 range from negligible (e.g., pramipexole) through intermediate (e.g., apomorphine) to pronounced (e.g., bromocriptine).
r␣ 2D -, h␣ 2A -, h␣ 2B -, and h␣ 2C -ARs. There was considerable (Ͼ10,000) variability in drug affinities for h␣ 2A -and r␣ 2D -ARs, ranging from quinerolane (negligible) to lisuride (very high), with piribedil, talipexole, and several other drugs showing intermediate values (Table 5 ). Only cabergoline revealed (slightly) higher affinity for r␣ 2D -versus h␣ 2A -ARs. No drug clearly differentiated h␣ 2 -AR subtypes, although pramipexole showed negligible affinity for h␣ 2C -versus h␣ 2A -and h␣ 2B -ARs. Bromocriptine and roxindole were the only drugs to show similar or weaker affinities at h␣ 2A -compared with h␣ 1 -AR subtypes.
h␤ 1 -and h␤ 2 -ARs. Only four ligands (lisuride, terguride, bromocriptine, and roxindole) displayed significant affinity for h␤ 1 -ARs (Table 5 ). Bromocriptine and roxindole showed similar affinity at h␤ 2 -ARs, whereas lisuride and terguride revealed higher affinity for h␤ 2 -compared with h␤ 1 -ARs. Compared with h␣ 2 -ARs, affinities at h␤ 1 -and h␤ 2 -ARs were relatively weak for all drugs, and only lisuride and terguride approached affinities seen at h␣ 1 -ARs.
h5-HT 1A Receptors. There was substantial (10,000-fold) variation in drug affinities at h5-HT 1A receptors varying from quinerolane (Ͻ5.0) to roxindole (9.9) ( Table 6) . Several other agents, such as bromocriptine and apomorphine, showed marked affinity for h5-HT 1A sites although others, such as piribedil and talipexole, showed only modest affinities.
h5-HT 1B and h5-HT 1D Receptors. Several drugs, including piribedil and talipexole, failed to recognize h5-HT 1B receptors, although others, such as cabergoline and pergolide, displayed modest affinities (Table 6 ). At structurally related h5-HT 1D receptors, affinities were generally elevated com- (Table 6 ). However, certain agents, including cabergoline and pergolide, showed substantially lower affinity for h5-HT 2C versus h5-HT 2A and h5-HT 2B receptors. No drug clearly differentiated h5-HT 2A from h5-HT 2B sites. There was marked (Ͼ100-fold) variability in drug affinities at h5-HT 2A , h5-HT 2B , and h5-HT 2C receptors in each case: piribedil, talipexole, and pramipexole, for example, showed low affinities compared with apomorphine, bromocriptine, and, in particular, cabergoline and pergolide.
H 1 Receptors. Affinities of drugs at H 1 receptors varied from negligible (for example, apomorphine, bromocriptine, piribedil, and pramipexole) to modest (for example, terguride and lisuride) ( Table 6) .
Interrelationship among Binding Sites: Correlation Matrix. An important and general feature of the correlation matrix was the lack of negative correlation coefficients, that is, in no case was high affinity at one receptor associated with low affinity at a second site (Table 7) . This feature was reflected in numerous statistically significant correlation coefficients among pairs of receptors (Table 8) . Some were unsurprising, such as between hD 2S and hD 2L receptors, among h␣ 1 -AR and h␣ 2 -AR subtypes and between h5-HT 2A and h5-HT 2C receptors. More notably, there were high correlation coefficients between affinities at hD 2S and hD 2L receptors on the one hand, and h5-HT 2A , h5-HT 2B , and h5-HT 2C receptors on the other. Furthermore, hD 5 , h5-HT 2C , and h5-HT 2A sites were well correlated. Similarly, high correlation coefficients were observed between hD 2 receptors and ␣ 1 -and ␣ 2 -AR subtypes. On the other hand, affinities at hD 4 receptors were poorly correlated with affinities at hD 2S , hD 2L , and hD 3 receptors, as well as other sites with the exception of H 1 receptors. H 1 receptors were themselves distinguished by relatively poor (and, in certain cases, nonsignificant) correlation coefficients with other receptor types.
Principle Components Analysis. Application of PCA to the pK i values revealed that almost 90% of variance could be accounted for by three axes: PC1, PC2, and PC3 (Figs. 1, 2 , and 3; Table 8 ). That is, a reduction of "dimensionality" from 21 to a "subspace" of three axes preserved almost the entire variance in the data. This permitted the construction of bidimensional "biplots" (1/2, 1/3, and 2/3) upon which both the drugs and the variables that contributed to their dispersion could be projected (Figs. 1-3) .
The majority of variance (76.3%) could be attributed to PC1. Upon projection of drugs onto the biplot, they distributed along its entire length with lisuride and terguride defining one extremity and quinerolane, quinpirole, pramipexole, and ropinirole the other. (Note that orthogonal dispersion along PC2 is not relevant to the notion of clustering along PC1.) TL99, piribedil, and talipexole migrated close to the latter group, whereas roxindole, cabergoline, bromocriptine, and pergolide were located near to lisuride and terguride. Superimposition of the 21 variables upon PC1 revealed that all were situated on, and contributed to, its leftward extension. This observation is in line with the high degree of correlation among pK i values ( Table 8 ) and indicates that PC1 is a composite axis to which numerous variables cojointly contribute. Accordingly, the "loading values" (correlation coefficients) for the majority of variables onto PC1 were generally high, with hD 2S /hD 2L and hD 1 receptors yielding the most pronounced values (Table 8) . Consistent with the relatively low correlation coefficients of hD 4 and H 1 receptors to other variables, their participation in PC1 was minor. This is indicated in Table 8 by their comparatively modest loading values onto PC1. In line with the absence of negative correlation coefficients in the correlation matrix, no variables were located at the opposite extremity of PC1 (Figs. 4 and 5) . This contribution of multiple variables to PC1 explains the important role of lisuride and terguride in its determination inasmuch as they presented high affinities for all receptors. In contrast, drugs located at the opposite extremity displayed modest or low affinities. Accordingly, other drugs were situated between the two limits of PC1 as a function of the magnitude of their overall affinities.
Axis PC2 accounted for 6.5% of variance. In line with the comparatively low correlation coefficients of hD 4 and H 1 sites versus h␣ 1 -AR subtypes (Table 7) , they defined its two extremes. Accordingly, hD 4 /H 1 sites and h␣ 1 -AR subtypes displayed, respectively, positive and negative loading values for this axis (Table 8 ). The location of bromocriptine at one limit of PC2 (Figs. 1 and 3) corresponds to its ϳ1,000-fold lower affinity at H 1 and D 4 receptors versus ␣ 1 -AR subtypes. Quinelorane and TL99 were dissociated from bromocriptine at the other extreme in line with their more pronounced affinity for H 1 and hD 4 versus h␣ 1 -AR subtypes. The other drugs were distributed in accordance with this schema. PC3 contributed 5.1% of variance to the data. The projections of variables indicate that h␤ 2 /h␤ 1 -ARs and H 1 receptors on the one hand, and hD 5 , h5-HT 2A , and h5-HT 2B receptors on the other, primarily underlay distribution of drugs along this axis. Correspondingly, the loading values of h␤ 2 /h␤ 1 -ARs and H 1 receptors onto PC3 were ϳ0.4 and positive, whereas those of h5-HT 2A and hD 5 receptors were similar but negative (Table 8 ). The location of cabergoline and pergolide at one limit of the axis (Figs. 2 and 3 ) reflects, thus, their markedly (Ͼ100-fold) higher affinity for h5-HT 2A and hD 5 sites compared with H 1 receptors and h␤ 1 /h␤ 2 -ARs. The position of lisuride at the opposite extreme, on the other hand, reflects its comparatively more pronounced affinity for h␤ 1 -and h␤ 2 -ARs as well as H 1 receptors.
Hierarchical (Cluster) Analysis of Global Drug Homology. From the dendrogram of overall drug homology generated by analysis of the total database, several drug clusters not apparent from inspection of the biplots could be recognized (Fig.  4) . It is pragmatic to comment the dendrogram in a direction opposite to that of its mathematical construction, and the most striking separation between drugs was at the first "node", which yielded two major subdivisions.
The first major group comprised quinpirole, quinelorane, ropinirole, pramipexole, piribedil, and talipexole, whereas the second comprised lisuride, terguride, roxindole, bromocriptine, cabergoline, pergolide, TL99, and apomorphine. Compared with drugs in the second group, drugs in the first group displayed low affinities for multiple classes of 5-HT receptor, and low affinities for hD 5 compared with hD 2S /hD 2L receptors. Drugs in this first cluster also showed low affinity for hD 1 and H 1 receptors and negligible affinity for h␤ 1 -and h␤ 2 -ARs, although this feature was also seen in certain drugs in the second major cluster. Within the first group, a marked similarity was apparent between quinelorane and quinpirole, and between pramipexole and ropinirole, which comprised two closely related subclusters. The other two agents, piribedil and talipexole, could be distinguished by their more pronounced affinities at h␣ 1 -AR subtypes as well as at h␣ 2A -ARs, h␣ 2C -ARs, and, less markedly, h␣ 2B -ARs.
Within the second major subdivision, lisuride and terguride revealed high affinities at all sites, notably, at h5-HT 2A and h5-HT 2C receptors, all subtypes of dopamine receptor and h␤ 1 -and h␤ 2 -ARs. Roxindole and bromocriptine constituted a closely related subcluster showing a similar overall pattern of affinities, notably sharing high affinity for h␣ 1 -AR subtypes. Overall, roxindole showed higher affinities, although this difference was only marked for hD 4 receptors. An additional pair of ligands displaying similar receptor binding profiles was formed by cabergoline and pergolide, with the former showing higher affinities at most sites. Both revealed low affinities for H 1 receptors and h␤ 1 -and h␤ 2 -ARs. The final couple of closely related drugs was TL99 and apomorphine, which showed less pronounced affinities at most sites than other drugs in this division.
Radar Plots. The radar representations of Fig. 5 complement the dendrogram in exemplifying similarities and differences among various drugs at specific receptor types discussed above.
Discussion
hD 2S and hD 2L Receptors. Although benzamides display contrasting affinities at hD 2L compared with hD 2S receptors, other classes of antagonist show similar affinity; likewise, all agonists examined to date (including several antiparkinsonian agents) revealed comparable affinities for these sites (Leysen et al., 1993) . The present observations extend such reports in demonstrating similar affinities of numerous antiparkinson drugs at hD 2S versus hD 2L sites. Such information is important because 1) D 2S versus D 2L sites present differential patterns of post-translational processing, coupling, regulation, and localization; 2) D 2S autoreceptors modulate DA release and may contribute to neuroprotective properties of antiparkinson agents; and 3) postsynaptic D 2S and (predominant) hD 2L sites, perhaps via contrasting interactions with D 1 receptors, differentially control motor function (Zou et al., 1999; Usiello et al., 2000) . hD 3 and hD 4 Receptors. Comparisons of affinities at hD 3 versus hD 2 sites should be made cautiously in the light of multiple affinity states of the latter (Mierau et al., 1995; Coldwell et al., 1999; Perachon et al., 1999) . Nevertheless, the high potency of all agents for hD 3 sites underscores their potential relevance to beneficial and/or undesirable properties of antiparkinson drugs (Millan et al., 2000b; Joyce, 2001) . The modest correlation coefficients of hD 4 to hD 2S / hD 2L /hD 3 receptors indicate distinctive structure-activity relationships, in line with the discovery of many selective hD 4 receptor antagonists. Bromocriptine and piribedil displayed modest affinity, and antagonist properties (Newman-Tancredi et al., 2002a) , at hD 4 receptors indicating, as discussed elsewhere, that their stimulation is not mandatory for clinical efficacy (Rondot and Ziegler, 1992; Jenner, 1995 Tables 4 to 6 . These values (a total of 294) were simultaneously analyzed in a "polydimensional" space, as described under Materials and Methods. Top (scatter diagram), plots the distribution of each parameter (specific binding sites) as a function of its contribution to the first two principle components (axes), which accounted for 76.27 and 6.53% of variance, respectively. Reflecting extensive, positive "covariance" indicated in Table 8 , all parameters (vectors) clustered in the same direction along axis 1. Within the plot, the "circle of correlation" is depicted. The degree of correlation among specific parameters is revealed by projection of vectors onto this circle, and by the angle between pairs of vectors, which is inversely correlated to their degree of correlation (Table 8) . For example, in the bottom left quadrant, all three ␣ 1 -AR subtypes are highly intercorrelated, whereas they are poorly correlated to hD 4 receptors located in the upper quadrant (Table 8 ). The tips of the vectors, when vertically or horizontally projected onto PC1 and PC2, respectively, yield loading values indicated in Table 8 . Bottom, drugs are superimposed upon PCs 1 and 2. S, 5-HT.
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may improve cognitive-attentional processing (Oak et al., 2000) . hD 1 and hD 5 Receptors. Surprisingly, affinities were well correlated between hD 1 and hD 2S /hD 2L sites, suggesting that structure-activity relationships are less distinct than might be imagined. Joint D 1 /D 2 receptor stimulation may improve therapeutic efficacy for drugs such as apomorphine and pergolide (Jenner, 1995; Markham and Benfield, 1997; Perachon et al., 1999; Aizman et al., 2000) . Functional interactions among (partially colocalized) D 1 and D 3 receptors are also of importance in the actions of L-DOPA and other antiparkinson agents (Karasinska et al., 2000; Joyce, 2001) . Nevertheless, the low affinities of clinically effective drugs, such as pramipexole and ropinirole, at hD 1 sites support the notion that their engagement is not requisite for therapeutic efficacy. Although we corroborate the preference of apomorphine for hD 5 versus hD 1 sites (Sunahara et al., 1991; Demchyshyn et al., 2000) , we found (ϳ5-fold) higher affinities of apomorphine, bromocriptine, lisuride, and pergolide at hD 5 receptors com- jpet.aspetjournals.org pared with these studies. One factor underlying this difference may be the use of Chinese hamster ovary versus COS-7 cells. Indeed, Kimura et al. (1995) (using GH4C1 cells) similarly concluded that the cell line confers distinctive binding properties to hD 1 and hD 5 receptors. D 5 sites are of significance in several respects: 1) multivariate analyses revealed that hD 5 affinities discriminate antiparkinson agents; 2) D 5 receptors are situated on striatal dopaminergic, cholinergic, and GABAergic neurons (Ciliax et al., 2000) ; and 3) antisense probes against D 5 and D 1 receptors potentiated and inhibited, respectively, induction of rotation by D 1 /D 5 agonists in unilateral substantia nigra-lesioned rats (Dziewczapolski et al., 1998) . Differential modulation of motor function is supported by the contrasting phenotypes of mice lacking D 5 versus D 1 receptors and their distinctive patterns of localization (Sibley, 1999; Ciliax et al., 2000) .
h␣ 2 and h␣ 1 -ARs. The observations herein amplify isolated studies (Uitti and Ahlskog, 1996) of antiparkinson agents at r␣ 1 -and r␣ 2 -ARs in demonstrating that many recognize h␣ 1 -and h␣ 2 -AR subtypes. The present data thus complement reports of the weak (agonist) interaction of pramipexole with r␣ 2 -ARs (Mierau et al., 1995) and of actions of apomorphine and bromocriptine at hippocampal r␣ 2 -ARs (Jackisch et al., 1985) . Furthermore, the high affinity of TL99 for h␣ 2 -AR subtypes amplifies observations with native r␣ 2 -ARs (Martin et al., 1983) . Of particular interest, whereas talipexole behaves as an agonist at ␣ 2 -ARs (Meltzer et al., 1989) , piribedil manifests antagonist properties. Correspondingly, in contrast to talipexole, piribedil reinforces corticolimbic adrenergic and cholinergic transmission (Millan et al., 2000c (Millan et al., , 2001a Gobert et al., 2002) , actions contributing to its favorable influence upon cognitive function and mood (Brefel-Courbon et al., 1998; Bezard et al., 2001; Maurin et al., 2001; Nagaraja and Jayashree, 2001) . Extending work with native ␣ 1 -ARs, bromocriptine, lisuride, terguride, and jpet.aspetjournals.org roxindole displayed high affinities at h␣ 1 -AR subtypes (McPherson and Beart, 1983; Uitti and Ahlskog, 1996) . Potent blockade of ␣ 1 -ARs may interfere with the influence of antiparkinson agents upon motor performance and perturb cardiovascular function (Hieble et al., 1995; Millan et al., 2000) . h␤ 1 and h␤ 2 -ARs. The finding that several drugs recognize h␤ 1 -and h␤ 2 -ARs is of interest. First, ␤ 1 /␤ 2 -ARs are excitatory to corticostriatal glutamatergic afferents (Niittykoski et al., 1999) . Second, they activate dopaminergic, adrenergic, and serotonergic pathways in cortex and nucleus accumbens (Millan et al., 2000; Tuinstra and Cools, 2000) . Third, stimulation of ␤ 1 /␤ 2 -ARs enhances cognitive function and improves mood (O'Donnell et al., 1994) . Fourth, stimulation and blockade of central ␤ 1 /␤ 2 -ARs elicits and blocks tremor, respectively (Wilms et al., 1999) .
h5-HT Receptors. Although all ligands showed some affinity for h5-HT 1A receptors, extending studies of native sites (Uitti and Ahlskog, 1996) , marked differences among antiparkinson agents were seen at 5-HT 2 receptor subtypes. High affinities of lisuride, terguride, cabergoline, and pergolide at h5-HT 2A (and h5-HT 2C ) receptors underpin studies showing that ergot-related compounds interact with native "5-HT 2 " receptors (Beart et al., 1986; Uitti and Ahlskog, 1996; Markham and Benfield, 1997; Fariello, 1998) . Interestingly, their marked serotonergic affinities were mimicked by the structurally distinct roxindole and apomorphine (Uitti and Ahlskog, 1996; Newman-Tancredi et al., 1999 (Beart et al., 1986) , an observation extended here to a further species and other drugs. Such actions at H 1 receptors are of potential importance. First, H 1 receptors modulate motor function, and inhibit and enhance striatal dopaminergic and cholinergic transmission, respectively (Bacciottini et al., 2001; Brown et al., 2001 ). Second, they influence arousal and cognition (Brown et al., 2001) . Third, H 1 receptor blockade encourages sleep and elicits sedation, a troublesome symptom of treated and untreated parkinsonian patients (Brown et al., 2001; Friedman and Factor, 2000) . Fourth, rats sustaining 6-hydroxydopamine lesions of the substantia nigra and Parkinson's Disease patients show an increase in striatal histaminergic innervation (Anichtchik et al., 2000) . Reflecting functional interplay among dopaminergic and cholinergic networks in basal ganglia, muscarinic antagonists suppress tremor and dyskinesias provoked by L-DOPA, although side effects compromise their utilization (Wilms et al., 1999; Bezard et al., 2001 ). However, antiparkinson agents tested herein did not occupy cloned, human M 1 receptors (for all drugs, pK i values of Ͻ6.0).
Hierarchical (Cluster) Analysis. High versus low affinities at multiple 5-HT and hD 5 receptors underpinned a major subdivision of agents into two groups. This association is intriguing because "selective" hD 1 /hD 5 receptor ligands show pronounced affinity for h5-HT 2A and h5-HT 2C receptors (Millan et al., 2001b) . Of drugs not interacting with serotonergic receptors, the data support experimental use of quinpirole and quinelorane as selective D 2 -like receptor agonists. Furthermore, inasmuch as the receptor profiles of ropinirole and pramipexole were very similar, they should display common functional effects distinguishable from those of cabergoline and roxindole and from older agents such as bromocriptine and apomorphine. As regards piribedil and talipexole, which likewise recognized dopaminergic but not serotonergic receptors, it is important to emphasize their opposite antagonist and agonist properties at ␣ 2 -ARs, respectively; indeed, piribedil seems to be unique in simultaneously activating D 2 /D 3 receptors and blocking ␣ 2 -ARs without markedly interacting with 5-HT receptors (Newman-Tancredi et al., 2002a,b) . On the contrary, among ligands with pronounced serotonergic properties, cabergoline and roxindole were remarkably similar to pergolide and bromocriptine, respectively. Terguride and TL99, on the other hand, closely resembled lisuride and apomorphine, respectively. Certain closely related drugs possess similar structures, for example, pergolide and cabergoline. However, ropinirole/pramipexole and piribedil/talipexole presented similar binding profiles despite their chemical distinctiveness. Thus, chemical structure does not provide a satisfactory basis for prediction of receptor binding profiles.
Principal Component Analysis. The compound nature of PC1, which accounted for 76% variance, reflects marked correlation among receptors. That is, with the exception of hD 4 and H 1 receptors, all receptor types made a pronounced contribution to PC1 (Table 8 ). In accordance with its generally high affinity, lisuride defined one extremity of PC1 in distinction to drugs of modest affinity, such as quinpirole, which migrated at the opposite limit. PC2 and PC3, nevertheless, proved discriminant in dissociating bromocriptine from TL99 based on low and high affinities, respectively, for H 1 /hD 4 receptors versus ␣ 1 -ARs. Furthermore, cabergoline was located at one limit of PC3 on the basis of higher affinity for hD 5 and h5-HT 2A versus h␤ 1 /h␤ 2 -ARs and H 1 receptors, whereas lisuride (high affinity at ␤ 1 /␤ 2 -ARs and H 1 receptors) defined the opposite extremity. Thus, PCA identified several receptors contributing to diversity in the binding profiles of antiparkinson agents. Within this framework, PCA also provided insights into relationships among the drug themselves as a function of their affinities at abovementioned and other sites. For example, reflecting their pronounced affinities for virtually all sites, lisuride and terguride comprised a subset of drugs (clustered together) when projected onto PC1, PC2, and PC3, whereas piribedil and talipexole were likewise adjacent to each other across all PCs, corresponding to their mixed dopaminergic-adrenergic profiles in the absence of serotonergic affinities.
General Discussion. Several general features of this novel multivariate approach should be evoked. First, although multivariate techniques have been used for evaluation of biochemical abnormalities in schizophrenia (Carlsson et al., 2001 ) and characterization of drug pharmacokinetic profiles (Ette et al., 2001) , this is their first systematic utilization for characterization of drug receptor-binding profiles. Whereas pairwise drug/drug and site/site comparisons can be misleading, multivariate strategies simultaneously analyze the entire database in a multidimensional space permitting hypothesis-free exploration of similarities and differences as a function of overall binding profiles. Although both drugs and variables must be selected, substantial databases (as herein) minimize the risk that an involuntary "bias" may distort analyses. Second, a precondition for multivariate procedures is a homogeneous and extensive database incorpo- rating many variables and drugs. Although onerous to generate, the database can be subsequently exploited for studies of other drugs under equivalent conditions. For example, in the search for antiparkinson agents presenting novel, binding profiles differing from known agents. Third, integration of in vivo parameters would be of considerable interest (Millan et al., 2000) . Fourth, multivariate analyses assume that drugs behave in an identical manner at specific receptor types. This is appropriate for structure-activity relationships focusing on drug potency but neglects potential differences in efficacy. This important issue was addressed by investigations of coupling (Newman-Tancredi et al., 2002a,b) , although currently, there is no solution to the integration of contrasting drug actions (agonist versus antagonist properties) into multivariate analyses. Fifth, similarities and differences in overall binding profiles of drugs provide a framework for interpretation of their contrasting functional profiles in vivo. Multivariate analyses facilitate, thus, predictions of the beneficial and deleterious actions of novel drugs and would be most appropriately performed before their therapeutic evaluation. Indeed, it would be of considerable interest to undertake direct therapeutic comparisons of drugs possessing contrasting receptorial profiles, for example, of antiparkinson agents behaving essentially as dopaminergic agonists compared with those displaying pronounced activity at serotonergic and/or adrenergic receptors. In focusing on specific parameters, such as dyskinesias, depressive symptoms, and memory, such studies could provide key clinical information concerning the drugs in question and, more generally, clarify the significance of particular classes of monoaminergic receptor in the control of motor function, cognition, and mood in Parkinson's disease.
Concluding Comments. This comprehensive, multivariate analysis of binding profiles of diverse antiparkinson agents revealed marked and unexpected heterogeneity, a conclusion amplified by efficacy studies (Newman-Tancredi et al., 2002a,b) . These observations of similarities and differences among antiparkinson agents provide a framework for improved interpretation of their experimental and clinical actions, and for a more thorough understanding of the functional significance of individual classes of monoaminergic receptor in Parkinson's disease. A multivariate strategy could instructively be applied to other agents, such as antidepressants and antipsychotics, for which actions at multiple classes of receptor are likewise critical in determining their functional profiles.
